504 results on '"Hofmann W. -K."'
Search Results
2. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
3. Detection of invasive pulmonary aspergillosis in critically ill patients by combined use of conventional culture, galactomannan, 1-3-beta-D-glucan and Aspergillus specific nested polymerase chain reaction in a prospective pilot study
4. Course of colonization by multidrug-resistant organisms after allogeneic hematopoietic cell transplantation
5. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
6. Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): OPTIMIZATION OF MDS PATIENT-DERIVED XENOGRAFT (PDX) MODELS BY COMPARISON OF NSG AND NBSGW MICE
7. 5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES
8. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
9. Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS
10. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE
11. Myelodysplastische Syndrome
12. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study
13. P103 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: AUGMENTED ACTIVITY OF THE ALVOCIDIB AND 5-AZACYTIDINE COMBINATION IN MYELODYSPLASTIC NEOPLASMS IS ASSOCIATED WITH THE PRESENCE OF ASXL1 MUTATIONS
14. P094 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INTERMEDIATE RISK KARYOTYPE BY IPSS-R CAN BE SEPARATED INTO 5 PROGNOSTICALLY DISTINCT SUBGROUPS IN MDS PATIENTS
15. P089 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: IMPROVED PROGNOSIS OF PATIENTS WITH MDS OVER FOUR DECADES: ANALYSIS FROM THE GERMAN MDS REGISTRY
16. P090 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: COMPARISON OF PROGNOSTICATION BY IPSS-M, IPSS-R AND AIPSS-MDS IN THE CONTEXT OF LIMITED AVAILABILITY OF MOLECULAR DATA IN DAILY CLINICAL PRACTICE
17. P047 - Topic: AS04-MDS Biology and Pathogenesis/AS04c-MDS Mouse models (GEMMS, PDX): OPTIMIZATION OF MDS PATIENT-DERIVED XENOGRAFT (PDX) MODELS BY COMPARISON OF NSG AND NBSGW MICE
18. O12 - 5-AZACYTIDINE IN COMBINATION WITH A NOVEL PAN-LYSYL OXIDASE INHIBITOR SYNERGISTICALLY RESTORES ERYTHROPOIESIS IN MYELODYSPLASTIC MALIGNANCIES
19. Molecular alterations in bone marrow mesenchymal stromal cells derived from acute myeloid leukemia patients
20. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis
21. Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia
22. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)
23. Allogeneic hematopoietic cell transplantation without fluconazole and fluoroquinolone prophylaxis
24. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
25. P771: PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY
26. Thrombopoietic Growth Factors — Managing Thrombocytopenia
27. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet
28. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
29. Growth Factors in the Treatment of Acute Lymphoblastic Leukemia
30. Therapy of Advanced MDS, AML Evolving from MDS, or Secondary AML with Idarubicin Ara-C, VP-16, Followed by G-CSF-Priming Exhibits High Remission Rate
31. Chemotherapy with Idarubicin, Ara-C,VP-16, Amsacrine, Followed by G-CSF and Maintenance Immunotherapy with Interleukin-2 for Patients with High-Risk Acute Myeloid leukemia: a 3-Years Follow-Up
32. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
33. MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure
34. Myelodysplastische Syndrome
35. Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML)
36. Patients with malignant hematological disorders treated on a palliative care unit: prognostic impact of clinical factors
37. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
38. O15 - Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche: BONE MARROW DERIVED STROMAL CELLS FROM MYELODYSPLASTIC SYNDROMES ARE ALTERED BUT NOT CLONALLY MUTATED IN VIVO
39. O02 - Topic: AS08-Treatment/AS08e-New developments - Preclinical studies: A PRE-CLINICAL PATIENT-DERIVED XENOGRAFT MODEL OF MYELODYSPLASTIC SYNDROMES DEMONSTRATES EFFICACY AND SAFETY OF ELTROMBOPAG
40. Störungen der Leukozyten mit besonderer Berücksichtigung der Agranulozytose
41. Myelodysplastische Syndrome (MDS)
42. Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA-microarray from primary clinical samples
43. Herausforderungen klinischer Forschung am Lebensende am Beispiel einer AMG-Studie.
44. Topic: AS08-Treatment/AS08e-New developments - Preclinical studies
45. Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche
46. SETBP1 mutation analysis in 944 patients with MDS and AML
47. Analysis of NUP98/NSD1 translocations in adult AML and MDS patients
48. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload
49. Myelodysplasien: Molekularer Hintergrund und klinische Implikationen
50. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.